Nuvilex, Inc. (OTCQB: NVLX), in conjunction with its subsidiary Knock-Out Technologies, Ltd. and joint venture partner Legacy Biotechnologies, Inc., report preliminary study findings undertaken with Alternia™, Nuvilex’s natural product cancer agent formulation.
